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Varicella-zoster virus (VZV) is the etiologic agent of
varicella (chickenpox) and herpes zoster. VZV was the
first herpesvirus isolated and propagated in cell culture
(Weller and Stoddard, 1952). The wild-type Oka strain
(parent Oka; P-Oka) was attenuated through cell culture
passage by Takahashi (1974), who described the efficacy
of this Oka-derived virus (V-Oka) as a vaccine. After 15
years of experience in clinical trials, the live attenuated
varicella vaccine was licensed in the United States in
1995, and V-Oka vaccines are available in many coun-
tries (Krause and Klinman, 1995). The varicella vaccine is
the only vaccine approved for preventing illness caused
by a human herpesvirus.
GENESIS OF THE VARICELLA VACCINE
From a clinical perspective, VZV is unusual in that
primary infection almost always causes acute illness
whereas the other human herpesviruses, including her-
pes simplex virus type 1 (HSV), the prototype of the
alphaherpesvirus subfamily, are usually acquired asymp-
tomatically. VZV is also transmissible in respiratory se-
cretions, making it highly contagious. Although varicella
is usually mild, it affected about 4 million children every
year in the United States before the vaccine was intro-
duced. The disease burden attributable to primary VZV
infection included hospitalization of 5 per 1000 cases
and a case fatality rate of 0.7 per 100,000 in the 1- to
4-year age group (Seward et al., 2000). Varicella morbid-
ity and mortality are associated most often with invasive
group A streptococcus and Staphylococcus aureus in-
fections and neurologic syndromes, including encepha-
litis and cerebellar ataxia. Healthy children at risk for
these and other complications could not be identified
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153before their onset. Therefore, varicella emerged as an
important target for vaccine prevention as other child-
hood viral diseases were controlled by immunization.
The two major challenges in developing the varicella
vaccine were how to attenuate the virus so that its
inoculation did not cause varicella and how to address
the neurotropism of VZV. As with HSV, VZV persists in
sensory ganglia and causes herpes zoster when it reac-
tivates. The pathogenesis of primary VZV infection be-
gins with mucosal inoculation, followed by an incubation
period of 10–21 days during which VZV probably spreads
to regional lymph nodes, initiates primary viremia, and
replicates in reticuloendothelial tissues; it culminates in
a secondary viremia with viral transport to epithelial
cells, where it produces the classic vesicular cutaneous
lesions. In contrast to HSV, cell-associated viremia is
critical for VZV pathogenesis and reflects its lymphotro-
pism (Moffat et al., 1995). Early experiments showed that
injection of wild-type VZV produces viremia and typical
varicella, even though infection by this “nonnatural” route
bypasses the early stages of pathogenesis (von Bo´kay,
1909). The wild-type Oka strain was attenuated using the
empiric approach of growth in nonhuman cells, taking
advantage of the fact that VZV replicates in guinea pig
embryo fibroblasts. After 11 passages in human lung
fibroblasts, P-Oka was passed six times in guinea pig
cells and transferred back to human lung fibroblasts to
create V-Oka stocks. Subcutaneous inoculation of V-Oka
did not cause illness in children, indicating that viremia
did not occur or was subclinical, and seroconversion
was elicited reliably (Takahashi, 1974). Because of the
extreme host range restriction of VZV, animal models
could not be used to assess whether this pattern of
altered V-Oka virulence was associated with diminished
neurotropism. Nevertheless, vaccine development pro-
ceeded based upon the rationale that more than 95% of
the population is infected with wild-type VZV by early
adult years and V-Oka was not expected to be any more
neurovirulent than wild-type VZV (Annunziato and Ger-
shon, 2000).
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The prelicensure clinical experience in the United
tates demonstrated that ;1000–3000 pfu or more of
-Oka elicited adaptive immunity when administered
ubcutaneously to healthy children (White, 1997; Annun-
iato and Gershon, 2000). One dose induced humoral
nd cell-mediated immunity in more than 95% of vaccine
ecipients. Immunization with varicella vaccine elicited
gG antibodies as well as VZV-specific helper and cyto-
oxic T cell responses directed against the major viral
lycoproteins and the immediate early transactivating
rotein IE62 (Arvin, 1998). The vaccine was less immu-
ogenic in children more than 12 years old and in adults,
ut a two-dose regimen induced humoral and cellular
esponses to VZV comparable to those observed in
ounger children given a single dose.
The varicella vaccine was protective in about 85% of
hildren evaluated in clinical trials and postlicensure.
his efficacy is sufficient to ensure significant clinical
enefit, although it is not equivalent to protection ob-
erved among naturally immune individuals. In addition,
he severity of the disease is usually modified when
accinated children and adults develop breakthrough
aricella after exposure to wild-type VZV. Using PCR
nalysis, these episodes have been shown to be caused
y superinfection with wild-type VZV rather than V-Oka
eactivation from latency (Annunziato and Gershon,
000). The mild symptoms suggest a suboptimal induc-
ion of adaptive immunity rather than primary vaccine
ailure. In clinical trials, susceptibility to breakthrough
aricella was associated with low or undetectable VZV
gG antibody titers 6 weeks after immunization (White,
997). While wild-type VZV entry at mucosal sites is not
locked, immunization appears to prime host responses,
llowing efficient clearance of VZV-infected T cells and
apid control of viral replication in cutaneous lesions,
hich often remain maculopapular rather than vesicular.
reexisting cellular immunity may account for the de-
reased severity of breakthrough varicella since the ki-
etics of the initial cell-mediated immune response cor-
elates with the extent of the rash during primary VZV
nfection (Arvin, 1998).
Protective efficacy appears to be sustained in most
accinees, indicating that secondary vaccine failure due
o waning immunity is unusual. Although VZV antibodies
ecame undetectable in 5% of vaccinees in one cohort,
ther longitudinal studies show persistent or increasing
ZV IgG titers and T cell responses to VZV (Johnson et
l., 1997; Zerboni et al. 1998). VZV-specific responder T
ell frequencies in vaccinees tested more than 5 years
fter immunization are equivalent to those of naturally
mmune individuals when compared by limiting-dilution
TL or intracellular cytokine assays (Arvin, 1998;
sanuma et al., 2000) (Fig. 1). Nevertheless, long-term
rotection cannot be assessed reliably until the annual
p
saricella epidemics diminish because, as is true of nat-
ral immunity, new exposures to wild-type VZV boost
accine-induced adaptive responses.
V-Oka vaccines are licensed to prevent serious vari-
ella, regardless of their impact on morbidity related to
erpes zoster. Nevertheless, whether vaccine-induced
mmunity wanes over time is also important because
ZV-specific responder T cell frequencies correlate with
FIG. 1. Responder cell frequencies of T cells that recognize varicella-
zoster virus (VZV) proteins after wild-type VZV infection or immunization
with varicella vaccine. (A) CTL frequencies in naturally immune donors
and vaccine recipients determined under limiting dilution conditions
using autologous lymphoblastoid cells infected with vaccinia recombi-
nants that expressed viral glycoproteins and IE62 protein as targets.
The X-axis indicates the responder cell frequency (RCF) 3 106. Dark
bars indicate mean RCF values for cytotoxic T cells from immune
donors that recognized each target protein, as indicated on the Y-axis.
(B) VZV-specific CD4 T cell frequencies in naturally immune (NI) and
vaccine recipients (vaccine) detected by intracellular cytokine assay
using interferon-g (IFNg) or tumor necrosis factor-a (TNFa) and CD69
taining for flow cytometry (mean 6 SE); no significant differences
ere observed (Asunama et al., 1999).reservation of VZV latency. Although V-Oka reactivates
ignificantly less often than wild-type VZV, herpes zoster
155MINIREVIEWdue to V-Oka has been documented (Annunziato and
Gershon, 2000). In addition, vaccinees may acquire wild-
type VZV subclinically, which can cause herpes zoster
later. Immunologic boosting from new exposures may be
important to preserve latency of V-Oka or wild-type VZV
in vaccinees.
At this point, two questions about the efficacy of vari-
cella vaccine remain unresolved. First, based upon the
FIG. 2. Infectious virus in SCID-hu skin implants infected with V-Oka
or P-Oka. Implants were inoculated with P-Oka (black bars) or V-Oka
(shaded bars) and harvested 14, 21, or 28 days postinfection. Cell-
associated virus was measured in an infectious focus assay and pfu
per implant was calculated (mean 6 SE). On day 21, all differences
between strains were statistically significant (P # 0.02, Student’s t
test) (adapted from Moffat et al., 1998).FIG. 3. Schema of the clinicahypothesis that antiviral memory immunity reflects the
magnitude of the initial antigen-specific T cell response,
increasing the infectious virus content of varicella vac-
cine might enhance responder cell frequencies elicited
during this “burst” and reduce the incidence of break-
through varicella. Second, if long-term memory immunity
requires periodic exogenous reexposure to VZV anti-
gens, revaccination may be necessary to sustain vaccine
efficacy when annual varicella epidemics are controlled.
ATTENUATION
The clinical markers of V-Oka attenuation are that
vaccine-associated rashes, either at the site of injection
or at distant sites, occur in only about 5% of healthy
children and adults and that replication of V-Oka is re-
stricted in vaccinees who have leukemia or other immu-
nosuppressive conditions that would predispose them to
life-threatening pneumonia, hepatitis, and encephalitis
with wild-type VZV infection (White, 1997; Annunziato and
Gershon, 2000). Diminished transmission is another
measure of V-Oka attenuation; susceptible close con-
tacts have not become infected unless the vaccinee had
cutaneous lesions, indicating that V-Oka is not shed in
respiratory secretions. Twenty percent of healthy sus-
ceptible siblings of leukemic children who developed
vaccine-related rashes had subclinical infection, com-
pared to less than 5% after wild-type VZV contact. Those
who developed secondary V-Oka infection had an aver-
age of 38 lesions instead of the 300–500 lesions ex-
pected with wild-type VZV infection. With respect to neu-
rovirulence, V-Oka is significantly less likely to cause
herpes zoster than wild-type VZV in healthy or immuno-
compromised children (Annunziato and Gershon, 2000).l attenuation of V-Oka.
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156 MINIREVIEWConceptually, the clinical attenuation of V-Oka might
occur without any genetic mutations in the viral genome.
By this model, the infectious virus inoculum, antigen
content, route of inoculation, and host factors, such as
age and immune competence, could combine to create
circumstances in which the host response controlled
V-Oka replication efficiently and blocked its pathogenic
potential. VZV replication in cell culture is associated
with production of defective particles and viral proteins
that are not incorporated into virions and antigen content
plays a role in varicella vaccine immunogenicity. Early
priming of the host response by the viral antigen content
of the vaccine may modulate V-Oka replication so that
signs of infection are prevented (Arvin, 1998). Vaccine-
related rashes occurred in 40% of children with leukemia
who were receiving chemotherapy compared with 11% of
those who had completed immunosuppressive treat-
ment, underscoring that the host response contributes to
clinical V-Oka attenuation.
Nevertheless, P-Oka and V-Oka have significant inher-
ent differences in virulence, as demonstrated in the
SCID-hu model of VZV pathogenesis in which host mod-
ulation of viral infectivity is not a factor (Moffat et al.,
1998). V-Oka exhibits a reduced virulence phenotype in
the SCID-hu skin model, with reduced yield of infectious
virus and decreased viral protein synthesis compared to
P-Oka and another low-passage clinical isolate (Fig. 2).
Prolonged growth in human cells alone was sufficient to
reduce skin replication since VZV-Ellen (.100 passages)
also replicated poorly. V-Oka and HSV-1 caused superfi-
cial lesions restricted to the epidermis, whereas P-Oka
invaded and destroyed cells in the dermal layer. In con-
trast, V-Oka showed no reduction in infectivity for CD41
nd CD81 T cells, indicating that skin and T cell tro-
isms are mediated by different virulence determinants
Moffat et al., 1998). In addition, V-Oka retains the capac-
ty to downregulate major histocompatibility class I ex-
ression which is observed on infected T cells as well as
ibroblasts (Abendroth et al., 2001). These experiments in
he SCID-hu model provide an explanation for the atten-
ation of Oka-derived vaccines compared to direct inoc-
lation of wild-type VZV, which causes typical varicella.
n healthy children. The delay in production of infectious
-Oka at the site of subcutaneous inoculation allows
ime for induction of adaptive VZV-specific immunity be-
ore viremia can occur, whereas V-Oka may escape from
nfected epithelial cells into T cells, causing viremia and
aricella-like symptoms in some immunocompromised
hildren (Fig. 3).
VZV was the first human herpesvirus to be sequenced
Davison and Scott, 1986), and initial analyses of the
-Oka and P-Oka genomes have been reported (Argaw
t al., 2000; Gomi et al., 2000; Faga et al., 2001). Multiple
nucleotide differences between P-Oka and V-Oka, which
are predicted to change amino acid residues, have been
identified in all classes of viral proteins. Of particularsignificance, the varicella vaccine appears to contain
viral subpopulations that harbor variable sequence
changes compared to P-Oka (Gomi et al., 2000). Our
comparative analysis of the V-Oka and P-Oka consensus
sequence data is accessible on the Internet: www.
stanford.edu/;jjcheng/VZV/ (Cheng et al., 2001); viral
proteins that have expected amino acid substitutions are
listed in Table 1. Some single-nucleotide polymorphisms
(SNPs) are present in the viral glycoprotein genes, in-
cluding gE, which is required for VZV replication, and
notably a number of SNPs are detected in ORF62, which
encodes the major immediate early transactivator, the
IE62 protein. Even single base pair changes in the gly-
TABLE 1
Analysis of Consensus Sequence Data for V-Oka and P-Oka
ORF Protein aa
1 (None) 2
6 DNA rep 2
8 dUTPase 1
9 (UL49/VP22) 1
10 Transactivator 3
11 (aTIF aux) insert/deletea
14 gC insert/deletea
16 DNA bp 1
17 (UL41/vhs) 3b
18 Ribo reductase 1
21 (UL37) 1
22 (UL36) 11c
24 (UL34) 1
28 DNA pol 3
29 ssDNA bp 3
31 gB 1
33 Protease 3
35 (UL24) 1
36 Thy kinase 1
37 gH 1
38 (UL21) 1
39 (UL20) frame shiftd
44 (UL16) 1
48 Alk exonucl 2
51 Ori bp frame shiftc
52 Helic/primase 3
54 (UL6) 2
56 (UL4) 1
57 (None) 1
58 (UL3) 3
60 gL 2
62/71 IE62 3
64/69 (US10) 1
68 gE 1
Note. Parentheses indicate HSV homologue if VZV protein is not
haracterized.
a Insertions/deletions in R repeats.
b With a 3-nt deletion.
c Two R-repeat insertion/deletion regions with 11-aa differences.
d Frame shift changes the C-terminus.coproteins are of interest because Santos et al. (2000)
found that the accelerated replication phenotype of VZV-
r
c
V
A
c
p
g
V
b
t
m
t
“
a
n
r
a
s
z
t
a
O
r
c
V
o
S
o
g
p
f
(
c
s
c
a
b
d
s
r
a
t
c
s
c
a
(
nants u
157MINIREVIEWMSP is due to one amino acid substitution in gE. Com-
paring ORF62 from V-Oka and several other VZV isolates,
Faga et al. (2001) noted 10 SNPs in this gene. With
espect to V-Oka attenuation, these more common
hanges may indicate sites that vary among wild-type
ZV strains and are therefore not likely to be attenuating.
lternatively, some changes in ORF62 may reflect cell
ulture growth since several of these viruses had been
assed extensively and could be related to the slow-
rowth phenotype of V-Oka in cutaneous epithelial cells.
ZV recombinants with targeted genetic mutations can
e made from cosmids (Cohen and Seidel, 1993). Using
he P-Oka cosmids that we have made to produce chi-
eric viruses with V-Oka cosmids (Mallory et al., 1995) or
o introduce specific nucleotide changes into the P-Oka
backbone” (Fig. 4) will allow the mapping of genetic
lterations that contribute to the V-Oka attenuation phe-
otype in the SCID-hu skin model.
The experimental analysis of V-Oka attenuation with
espect to neurovirulence remains blocked by the lack of
ppropriate models of VZV interaction with cells of the
ensory ganglia. The clinical observation that herpes
oster is less common in vaccinees could simply reflect
he fact that the usual interval between primary infection
nd VZV reactivation is many decades. Alternatively, V-
ka may have reduced capacities to establish latency,
eactivate, or cause clinical signs of herpes zoster be-
ause of its limited infectivity in skin. Less replication of
-Oka in skin could influence the extent of “colonization”
FIG. 4. Generation of V-Oka and P-Oka recombif dorsal root ganglia by retrograde axonal transport.
ince VZV disseminates hematogenously, the absencef viremia might also limit V-Oka infection of sensory
anglia. The “viral load” of wild-type VZV in ganglia ap-
ears to be much lower than HSV, perhaps accounting
or the much less frequent episodes of VZV reactivation
Pevenstein et al., 2000). Whether V-Oka has even less
apacity to reactivate than wild-type VZV remains unre-
olved.
CONCLUSION
The licensure of V-Oka vaccines is based upon the
linical documentation of their safety, immunogenicity,
nd efficacy. In the United States, analyses of the mor-
idity and mortality due to primary VZV infection pre-
icted that health benefits would be optimal with univer-
al immunization. Varicella vaccine is recommended for
outine administration to children at 12–15 months of age
nd for older susceptible children and adults. The rein-
roduction of wild-type VZV from herpes zoster cases
reates a challenge for breaking the cycle of transmis-
ion, but from a long-term perspective, VZV might be-
ome the first human herpesvirus to be eradicated after
n estimated 70 million years of coevolution with its host
McGeogh and Davison, 1999).
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